Listen to this page using ReadSpeaker
Posts tagged arvo

ARVO 2014: LCA Gene Therapy Recipient Featured During Keynote

Yannick Duwe and his father, Tony, at ARVOGene-therapy pioneer Jean Bennett, M.D., Ph.D., may have been the keynote speaker for the closing session at the annual meeting of the Association for Research in Vision and Ophthalmology (ARVO), but Yannick Duwe, a 15-year-old patient with Leber congenital amaurosis (LCA) who was treated in her clinical trial six years ago, stole the show. He and his father, Tony, were part of a panel which also included members of Dr. Bennett’s research team.
Continue Reading…

ARVO 2014: European Collaboration Developing Cross-Cutting, Vision-Saving Therapies

The DRUGSFORD collaborativeOne of the most intriguing reports on therapy development at the annual meeting of the Association for Research in Vision and Ophthalmology came from a European collaborative project called DRUGSFORD, which is derived from the phrase “drugs for retinal degeneration.” With funding from the European Union, the project brings together three research groups and two companies to develop a therapy that can treat a disease pathway common to many retinal degenerations. Simply put, they’re creating therapies that can save vision in as many people as possible, independent of the genetic cause of disease.
Continue Reading…

ARVO 2014: Three Promising CEP290 Gene Therapy Alternatives

Renee Ryalls explains the dual-AAV gene therapy she's developing.While gene therapies for retinal degenerative diseases are making groundbreaking strides in both human and laboratory studies, the most widely and successfully used human-engineered virus for delivering replacement genes to retinal cells — the adeno-associated virus, or AAV — has one significant limitation. It can’t deliver relatively large genes, namely those larger than about 4.5 or 5 kilobases (kb). (Bases are the building blocks of a gene, and its size is expressed in kilobases.)
Continue Reading…

ARVO 2014: The Latest Retinal Research News from the Magic Kingdom

The Foundation’s science team is in Orlando over the next week for the annual meeting of the Association for Research in Vision in Ophthalmology, which convenes more than 10,000 of the world’s top eye researchers to report on their latest achievements.
Continue Reading…

Grow Your Own: Harnessing Muller Glia for Retinal Regeneration

As I wind down the week at the annual meeting of the Association for Research in Vision and Ophthalmology (ARVO), I’d like to introduce an intriguing therapeutic approach to retinal degeneration that would be a home run if perfected. It’s called retinal regeneration, and it happens to be right in line with the National Eye Institute’s life-changing audacious goal, announced on Monday: “to regenerate the neurons and neural connections in the eye and visual system.”
Continue Reading…

ARVO Update on Optogenetics: New Light for People with Advanced Vision Loss

Keirnan Willett.One of the promising emerging approaches to restoring vision in people with advanced retinal diseases is a form of therapy known as optogenetics. In essence, this type of treatment restores light sensitivity — and, potentially, meaningful vision — to people who have very little, if any, vision remaining. An important benefit of optogenetics is that it should work regardless of the underlying genetic defect causing the disease. While it is too early to speculate how well optogenetics will ultimately work, we’re hoping it ends up retiring a lot of white canes. Continue Reading…

RP Gene Therapy Clinical Trial Update from ARVO

Drs. Nicola Ghazi (left) and Doug Vollrath. I am always pleased to hear reports on human studies for retinal diseases. And such is the case with a research poster I just reviewed at the Association for Research in Vision and Ophthalmology (ARVO) annual meeting. It described a new clinical trial underway for a potentially life-changing gene therapy for people with autosomal recessive retinitis pigmentosa (MERTK mutations) taking place at King Khaled Eye Specialist Hospital in Saudi Arabia.
Continue Reading…

Retinal Regeneration is Major Focus of NEI’s Audacious Goal

Paul SieivingThe National Eye Institute (NEI) just announced that fighting blindness — retinal degenerations, in particular — has gotten audacious. It’s potentially life-changing news for people with these difficult conditions.
Continue Reading…

Stay Tuned for Daily Updates on “Life-Changing Research” from ARVO

ARVO 2013 discuss some of the posters on displayI am excited to be reporting to you live from Seattle where about 10,000 of the world’s top eye researchers are convening for the annual meeting of the Association for Research in Vision and Ophthalmology (ARVO). While researchers from many different ophthalmic fields are present at ARVO, it is the world’s largest gathering of retinal scientists. Continue Reading…

ARVO Update: Powerful Protein Positioned Well for Human Study

Dr. José Sahel

Dr. José Sahel

If you or someone you’re close to has a retinal degenerative disease, you should know about the vision-saving promise of a protein called Rod-derived Cone Viability Factor (RdCVF). It was discovered by Foundation-funded clinician-researchers Drs. José Sahel and Thierry Léveillard, of Institut de la Vision in Paris. In fact, they won the Foundation’s Board of Director’s Award in 2005 for the finding. It was a monumental effort, namely because they screened thousands of proteins to come up with the gem.

Continue Reading…